Mandated Part D Rebates Cannot Be Imposed Without Consequence To Beneficiaries, Holtz-Eakin Writes
This article was originally published in The Pink Sheet Daily
In a Health Affairs Blog post, former CBO Director Douglas Holtz-Eakin takes issue with a recent article arguing that mandated Part D rebates would not lead to major Medicare premium increases or otherwise shift costs to Part D beneficiaries as well as employers.
You may also be interested in...
Some patient groups ask Congress not to consider Medicaid-style rebates for dual-eligibles and low-income subsidy recipients in Medicare Part D; 72% of office-based physicians are using electronic health records; disparities in Medicaid EHR adoption, based on allocation of incentive payments, mirror those found in Medicare EHR adoption.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.